Researchers from the University Rey Juan Carlos University and PSL Paris have developed a new photosensitizer nanoparticles of silicon dioxide and ruthenium. These drugs are activated by light, if the cancer cells and contribute to their removal, photodynamic therapy is less invasive for the patient.
Studies have studied the formulation of the mesoporous silica nanoparticles less than 80 nm with a derivative of ruthenium. / URJC
Using metalofármacos, metal compounds with chemotherapeutic properties in treating cancer is of great concern to patients with various types of tumors. An estimated 60% of all cancer patients was treated with the compounds of metals, in particular platinum, at least once during the development of the disease.
However, these metal compounds have several problems in therapeutic use for it a large number of side effects and the possibility that the tumor becomes stable. They also create problems of solubility in biological media, and restrictions on the doses may be administered in some patients with problems in the immune system, resulting tumor progression.
Nanoformulations development of new drugs to be used in a variety of less aggressive treatments, such as photodynamic is one of research areas in which the group-NANO comets from Rey Juan Carlos University works. "These methods are based on drugs are called photosensitizers that after exposure to a certain light with certain characteristics, produces a special form of oxygen which can act against cancer cells that carry them to death" explains Sant & # 39; Yaga Gomez-Ruiz, the group researchers Nana comet.
The photosensitizer is used, thus for photodynamic therapy. If cancer cells are absorbed and are exposed to light, the drug is activated and destroy cancer cells.
The last command in this field has addressed the nanoparticle preparation of the mesoporous silica of less than 80 nm with a derivative of ruthenium (Ru metal with low toxicity), which has photodynamic activity under UV light. "Our goal is to explore the possibilities of these systems ruthenium nanomaterial and the like in the photodynamic therapy of various tumors," says Gomez-Ruiz.
This work with the & # 39 is a collaboration with Professor Gilles Gasser (ERC Consolidator) with chimie ParisTech PSL University of Paris (France) and researchers from the University of Zurich (Switzerland). It was published in the journal Dalton Transactions but what it has not yet been published in a special issue on "bioinspired reactivity of coordination compounds".
innovative products and future clinical trials
Currently there is only one drug from a ruthenium compound is studied in clinical trials, GAP-1433 prepared by the research group of Mc Farland (UNC Greensboro, USA). Researchers at the University PSL URJC and Paris showed that metallopharmaceutical nanoformulación ruthenium improves outcomes studied cell death in cancer cells after the application of light, opening the door for future clinical trials of this type of therapeutic compounds.
In Sant & # 39; Yaga Gomez-Ruiz promotes "In this sense, our work is focused on drugs that can be activated with less energy and more benign patient light than UV-A, such as red or infrared light which would excellent candidates for immediate use in some tumors therapeutic interest today. "